HC Wainwright & Co. has reiterated its buy rating for iovance biotherapeutics (IOVA.US), with a target price of $32.00.
HC Wainwright & Co.：重申Iovance Biotherapeutics(IOVA.US)评级，由买入调整至买入评级, 目标价由32.00美元调整至32.00美元。
HC Wainwright & Co. has reiterated its buy rating for iovance biotherapeutics (IOVA.US), with a target price of $32.00.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.